The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Boehringer Ingelheim; Roche
Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM).
 
Max S. Topp
Honoraria - Amgen
Consulting or Advisory Role - Affimed Therapeutics; Amgen; Gilead Sciences; Jazz Pharmaceuticals; Regeneron; Roche
Speakers' Bureau - Amgen
Research Funding - Affimed Therapeutics
Patents, Royalties, Other Intellectual Property - Biomarkers for Immunotherapies
Expert Testimony - Affimed Therapeutics; Amgen; Boehringer Ingelheim; Regeneron
Travel, Accommodations, Expenses - Affimed Therapeutics; Amgen; Roche
 
Michel Attal
No Relationships to Disclose
 
Christian Langer
No Relationships to Disclose
 
Philippe Moreau
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda
 
Thierry Facon
No Relationships to Disclose
 
Johannes Düll
No Relationships to Disclose
 
Benjamin Hebraud
No Relationships to Disclose
 
Carlos Gomez-Roca
No Relationships to Disclose
 
Gerd Michael Munzert
Employment - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim
 
Edith Gracien
Employment - Boehringer Ingelheim
 
Gerhard Zugmaier
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Patents, Royalties, Other Intellectual Property - Amgen
 
Hermann Einsele
No Relationships to Disclose